Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 23Gynecologic 2Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 34Magnetic Resonance Spectroscopy 31Specimen Handling 20Radiation 13Radiotherapy 12Biopsy 12Nivolumab 11Radiosurgery 10Bevacizumab 10X-Rays 9Nuclear Medicine Department, Hospital 7Lomustine 7Cyclophosphamide 7Carboplatin 7Vincristine 6Cisplatin 6trametinib 5Phantoms, Imaging 5Irinotecan 5Ipilimumab 5AZD 6244 5ulixertinib 4pembrolizumab 4erdafitinib 4dinutuximab 4dabrafenib 4binimetinib 4abemaciclib 4Platinum 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ribociclib × CNS × 30 days × Clear all
NCT05843253 2026-05-29

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Nationwide Children's Hospital

Phase 2 Recruiting
120 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡